1. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Updated Nov 20 2019. https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf. Accessed Sept 7 2022
2. Protocol template for phase 2 and 3 clinical trials that require FDA-IND or IDE application. National Institutes of Health (NIH). Updated Apr 7 2017. https://grants.nih.gov/policy/clinical-trials/protocol-template.htm. Accessed Sept 7 2022
3. Common Protocol Template (CPT). TransCelerate BioPharma INC, Clinical Content & Reuse Solutions. Updated 2021. https://www.transceleratebiopharmainc.com/assets/clinical-content-reuse-solutions/. Accessed Sept 7 2022
4. Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment, Guidance for Industry. U.S. Food and Drug Administration (FDA). Updated Dec 16 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-rhinosinusitis-nasal-polyps-developing-drugs-treatment. Accessed Feb 27 2023
5. Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease. European Medicines Agency (EMA). Updated Sept 1 2018. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf. Accessed Mar 7 2023